Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Rhythm Pharmaceuticals Inc (RYTM) USD0.001

Sell:$21.06 Buy:$21.09 Change: $0.17 (0.80%)
NASDAQ:0.05%
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
Sell:$21.06
Buy:$21.09
Change: $0.17 (0.80%)
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
Sell:$21.06
Buy:$21.09
Change: $0.17 (0.80%)
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Contact details

Address:
222 Berkeley St Fl 12
BOSTON
02116-3733
United States
Telephone:
+1 (857) 2644280
Website:
www.rhythmtx.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RYTM
ISIN:
US76243J1051
Market cap:
$934.31 million
Shares in issue:
43.93 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Meeker
    Independent Chairman of the Board
  • Keith Gottesdiener
    President, Chief Executive Officer, Director
  • Hunter Smith
    Chief Financial Officer, Treasurer
  • Nithya Desikan
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.